|Articles|November 8, 1995

Cytogen completes Cellcor purchase

Monoclonal antibody firm Cytogen of Princeton, NJ, has completedits purchase of Cellcor, a biotech therapy developer based inNewton, MA (SCAN 7/19/95). Cellcor has been merged into Cytogenas a wholly owned subsidiary, Cytogen

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Cytogen completes Cellcor purchase

Newsletter

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Nevada

(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

26th Annual International Lung Cancer Congress

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | South Carolina

43rd Annual CFS®: Innovative Cancer Therapy for Tomorrow™

20th Annual New York Lung Cancers Symposium®

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | West Virginia

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Tennessee

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

23rd Annual Winter Lung Cancer Conference®

2nd Annual Hawaii Cancer Conference

43rd Annual Miami Breast Cancer Conference®

19th Annual New York GU Cancers Congress™

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

17th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Radioligand Therapy 101: The Science Behind the Strategy

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

2026 International Symposium of Gastrointestinal Oncology (ISGIO)

26th Annual International Lung Cancer Congress

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Trending on Diagnostic Imaging

FDA Grants Fast Track Designation to Emerging Ultrasound Contrast Agent

Large Mammography Study Examines Contributing Factors with Higher False-Negative Rates

Study Finds That Over 70 Percent of Emergency CT Referrals Are ‘Inadequate’